Eli Lilly says obesity drugs not for 'cosmetic' use amid digital-sales push
Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for 'cosmetic' weight loss.
Stay updated with breaking news from Executive David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for 'cosmetic' weight loss.
Order Reprints Text size Lilly is entering the field of gene editing with a deal for Prevail Therapeutics. Frederick Florin/AFP via Getty Images Sales of a Covid-battling antibody helped allow Eli Lilly to lift its sales forecast for this year and tell Wall Street to expect better results than analysts had anticipated for 2021. In a Tuesday morning business update, the drug giant (ticker: LLY) said it could earn as much as $7.65 a share this year, and $8.40 the next. Lilly also disclosed a move into the burgeoning field of gene editing, with the $1 billion acqu...